The Brand Name CLOPIXOL DEPOT Has Generic Salt :: Zuclopenthixol
CLOPIXOL DEPOT Is From Company Lundbeck Priced :: Rs. 224.9
CLOPIXOL DEPOT have Zuclopenthixol is comes under Sub class Anti Psychotics of Main Class Nervous System
Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Psychotics
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Schizophrenia, Psychoses, Bipolar mania
Drug Dose ::
Adult: PO Psychoses Initial: 20-30 mg/day in divided doses. Maintenance: 20-50 mg/day. Max: 150 mg/day. IM Acute psychosis As acetate ester: 150 mg, repeat if needed 2-3 days later. Max cumulative dose: 400 mg/course. Max number of inj: 4/course. Max duration: 2 wk. Chronic psychosis As decanoate ester: Initial: 100 mg as test dose, followed after at least 1 wk by 200-500 mg or more, repeated at 1-4 wkly if needed. Max: 600 mg/wk. Inj >2 mL to be distributed between 2 inj sites.
Hypersensitivity. Comatose states e.g. alcohol, barbiturate and opiate intoxications; porphyria. children.
Drug Precautions ::
Hepatic and renal impairment, heart disease, recent acute MI, arrhythmias, significant bradycardia (<50 beats>Drug Side Effects ::
Drowsiness, blurred vision, tachycardia, nausea, dizziness, headache, excitement, postural hypotension, hyperprolactinaemia, sexual dysfunction, ECG changes (prolongation of QT interval and T wave changes), hyperthermia. Extrapyramidal symptoms may occur, especially during the early phase of treatment; urinary frequency or incontinence; tardive dyskinesia. Potentially Fatal: Neuroleptic malignant syndrome, blood dyscrasias.
Pregnancy category ::
Drug Mode of Action ::
Zuclopenthixol has high affinity for D1 and D2 receptors and ?-adrenoreceptors. It also has slight antihistamine properties and blocks serotonergic properties.
Drug Interactions ::
Zuclopenthixol may enhance the sedative effects of alcohol and the effects of barbiturates and other CNS depressants. Zuclopenthixol reduces the antihypertensive effect of guanethidine. Concomitant use of metoclopramide and piperazine with zuclopenthixol increases the risk of extrapyramidal symptoms. Increased risk of severe neurotoxicity with lithium and sibutramine. Increased anticholinergic side effects with drugs with anticholinergic properties. Potentially Fatal: Antagonises effect of apomorphine, levodopa and other dopamine agonists. Increased risk of blood dyscrasias with clozapine. Increased risk of arrhythmias with dugs that prolong QT interval e.g. class Ia and III antiarrhythmics, erythromycin or cause electrolyte disturbances e.g. thiazide diuretics.